{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:51:40Z","timestamp":1786125100518,"version":"build-2736575974"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:00:00Z","timestamp":1535587200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurosurg.","NEUROS"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current standard treatment of microprolactinomas is dopamine agonist therapy. As this drug treatment is lifelong in up to 80% of cases, many patients consult pituitary surgeons regarding a surgical alternative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify prognostic criteria for surgical remission, we reviewed outcomes of our series of microprolactinomas treated with endoscopic transsphenoidal surgery, with a special emphasis on magnetic resonance adenoma delineation and position.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our study cohort comprises a single center series of 60 patients operated for histopathologically verified magnetic resonance imaging unequivocally identifiable endosellar microprolactinoma between 2003 and 2017. In 31 patients the adenoma was enclosed by pituitary gland (group ENC), in 29 patients the adenoma was located lateral to the gland adherent to the medial cavernous sinus wall (group LAT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After a mean follow-up of 37 mo (range 4-143 mo), remission rate was significantly higher in adenomas enclosed by pituitary gland (group ENC) than adenomas located lateral to the gland (group LAT), with 87% vs 45%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a0.01. Intraoperatively, 4 patients showed signs of invasiveness. Preoperative prolactin levels did not differ between the groups (mean 155 and 187 ng\/ml in group ENC and LAT, respectively).\n                    <\/jats:p>\n                    <jats:p>\n                      A binary logistic regression model revealed that only the radiological criteria applied showed a significant correlation (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a0.003) with endocrine remission.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>According to our results, remission rate is significantly higher in microprolactinomas enclosed by the pituitary gland. However, the decision for surgery should take into account surgeons experience and possibility of complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuros\/nyy385","type":"journal-article","created":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T23:08:43Z","timestamp":1534374523000},"page":"508-515","source":"Crossref","is-referenced-by-count":30,"title":["Endoscopic Transsphenoidal Surgery of Microprolactinomas: A Reappraisal of Cure Rate Based on Radiological Criteria"],"prefix":"10.1227","volume":"85","author":[{"given":"Alexander","family":"Micko","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Medical University Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greisa","family":"Vila","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Division of Endocrinology and Metabolism, Medical University Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"H\u00f6ftberger","sequence":"additional","affiliation":[{"name":"Institute of Neurology, Medical University Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engelbert","family":"Knosp","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Medical University Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Wolfsberger","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Medical University Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,10]]},"reference":[{"issue":"5","key":"bib1-20231011","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrendo.2011.37","article-title":"Medical treatment of prolactinomas","volume":"7","author":"Colao","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"bib2-20231011","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","article-title":"Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)","volume":"72","author":"Fernandez","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"bib3-20231011","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients","volume":"84","author":"Verhelst","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"bib4-20231011","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2265.1993.tb02372.x","article-title":"The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study","volume":"39","author":"Webster","year":"1993","journal-title":"Clin Endocrinol"},{"issue":"9","key":"bib5-20231011","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/BF03348016","article-title":"Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients","volume":"20","author":"Muratori","year":"1997","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"bib6-20231011","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00701-016-2762-z","article-title":"Reasons and results of endoscopic surgery for prolactinomas: 142 surgical cases","volume":"158","author":"Akin","year":"2016","journal-title":"Acta Neurochir"},{"issue":"2","key":"bib7-20231011","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3171\/jns.2002.97.2.0307","article-title":"Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery","volume":"97","author":"Amar","year":"2002","journal-title":"J Neurosurg"},{"issue":"3","key":"bib8-20231011","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11102-010-0283-y","article-title":"Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists","volume":"14","author":"Babey","year":"2011","journal-title":"Pituitary"},{"issue":"4","key":"bib9-20231011","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.3171\/2011.1.FOCUS10317","article-title":"Endoscopic endonasal transsphenoidal surgery for functional pituitary adenomas","volume":"30","author":"Hofstetter","year":"2011","journal-title":"Neurosurg Focus"},{"issue":"6","key":"bib10-20231011","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S1072-7515(01)01101-2","article-title":"The surgical management of pituitary adenomas in a series of 3,093 patients1 1No competing interests declared","volume":"193","author":"Jane","year":"2001","journal-title":"J Am Coll Surg"},{"issue":"1","key":"bib11-20231011","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EJE-07-0248","article-title":"Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients","volume":"158","author":"Kreutzer","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"bib12-20231011","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3325\/cmj.2012.53.224","article-title":"Endocrinological outcomes of pure endoscopic transsphenoidal surgery: a Croatian Referral Pituitary Center experience","volume":"53","author":"Maric","year":"2012","journal-title":"Croat Med J"},{"issue":"1","key":"bib13-20231011","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1530\/eje.0.1400043","article-title":"Trans-sphenoidal surgery for microprolactinoma: An acceptable alternative to dopamine agonists?","volume":"140","author":"Turner","year":"1999","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"bib14-20231011","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00006123-199902000-00006","article-title":"Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results","volume":"44","author":"Tyrrell","year":"1999","journal-title":"Neurosurgery"},{"issue":"1","key":"bib15-20231011","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1042-3680(02)00090-6","article-title":"Role of surgery in the treatment of microprolactinomas","volume":"14","author":"Couldwell","year":"2003","journal-title":"Neurosurg Clin N Am"},{"issue":"4","key":"bib16-20231011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/foc.2004.16.4.3","article-title":"Contemporary management of prolactinomas","volume":"16","author":"Liu","year":"2004","journal-title":"Neurosurg Focus"},{"issue":"4","key":"bib17-20231011","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.nec.2012.06.010","article-title":"Medical versus surgical management of prolactinomas","volume":"23","author":"Oh","year":"2012","journal-title":"Neurosurg Clin N Am"},{"issue":"10","key":"bib18-20231011","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/ncpendmet0290","article-title":"Management of resistant prolactinomas","volume":"2","author":"Olafsdottir","year":"2006","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"bib19-20231011","first-page":"125","article-title":"Cost-Effectiveness analysis of surgical versus medical treatment of prolactinomas","volume":"78","author":"Zygourakis","year":"2017","journal-title":"J Neurol Surg B Skull Base"},{"issue":"3","key":"bib20-20231011","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11102-008-0091-9","article-title":"Quality of life in women with microprolactinoma treated with dopamine agonists","volume":"11","author":"Cesar de Oliveira Naliato","year":"2008","journal-title":"Pituitary"},{"issue":"1","key":"bib21-20231011","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"bib22-20231011","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.wneu.2015.10.090","article-title":"Cost-effectiveness analysis of microscopic and endoscopic transsphenoidal surgery versus medical therapy in the management of microprolactinoma in the United States","volume":"87","author":"Jethwa","year":"2016","journal-title":"World Neurosurg"},{"issue":"1","key":"bib23-20231011","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","article-title":"Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis","volume":"95","author":"Dekkers","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"bib24-20231011","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3171\/2014.12.JNS141083","article-title":"Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification","volume":"122","author":"Micko","year":"2015","journal-title":"J Neurosurg"},{"issue":"6","key":"bib25-20231011","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.wneu.2014.07.032","article-title":"An advanced navigation protocol for endoscopic transsphenoidal surgery","volume":"82","author":"Mert","year":"2014","journal-title":"World Neurosurg"},{"issue":"2","key":"bib26-20231011","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"bib27-20231011","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12022-017-9498-z","article-title":"Overview of the 2017 WHO classification of pituitary tumors","volume":"28","author":"Mete","year":"2017","journal-title":"Endocr Pathol"},{"issue":"3","key":"bib28-20231011","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-11-0656","article-title":"Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels","volume":"166","author":"Shimazu","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"bib29-20231011","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"issue":"13","key":"bib30-20231011","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMcp0912025","article-title":"Clinical practice. Prolactinomas","volume":"362","author":"Klibanski","year":"2010","journal-title":"N Engl J Med"},{"issue":"8083","key":"bib31-20231011","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(78)91764-6","article-title":"Radiological evidence for regression of prolactinoma after treatment with bromocriptine","volume":"2","author":"Sobrinho","year":"1978","journal-title":"Lancet"},{"issue":"14","key":"bib32-20231011","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"issue":"1","key":"bib33-20231011","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11102-010-0261-4","article-title":"Effect of dopaminergic drug treatment on surgical findings in prolactinomas","volume":"14","author":"Menucci","year":"2011","journal-title":"Pituitary"},{"issue":"1","key":"bib34-20231011","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2265.2011.04326.x","article-title":"Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study","volume":"77","author":"Delgado","year":"2012","journal-title":"Clin Endocrinol"},{"issue":"12","key":"bib35-20231011","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1742-1241.2008.01779.x","article-title":"Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia","volume":"62","author":"Bogazzi","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"3","key":"bib36-20231011","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11102-008-0134-2","article-title":"Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas","volume":"12","author":"Vallette","year":"2009","journal-title":"Pituitary"},{"issue":"3","key":"bib37-20231011","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000180100","article-title":"Follow-up of children born of bromocriptine-treated mothers","volume":"22","author":"Raymond","year":"1985","journal-title":"Horm Res"},{"issue":"1","key":"bib38-20231011","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2265.2007.03000.x","article-title":"Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study","volume":"68","author":"Colao","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"bib39-20231011","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2265.2010.03808.x","article-title":"Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women","volume":"73","author":"Lebbe","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"bib40-20231011","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.fertnstert.2015.07.1132","article-title":"Pregnancy outcomes in women with growth hormone deficiency","volume":"104","author":"Vila","year":"2015","journal-title":"Fertil Steril"},{"issue":"4","key":"bib41-20231011","first-page":"257","article-title":"[Cost-effectiveness analysis of two therapeutic methods for prolactinoma]","volume":"43","author":"Zhen","year":"2008","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"issue":"10","key":"bib42-20231011","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1210\/jc.2003-030461","article-title":"Transsphenoidal surgery for pituitary tumors in the United States, 1996\u20132000: mortality, morbidity, and the effects of hospital and surgeon volume","volume":"88","author":"Barker","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"bib43-20231011","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1210\/jcem.87.7.8645","article-title":"Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome","volume":"87","author":"Losa","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"bib44-20231011","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/01616412.2017.1296653","article-title":"Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: A systematic review and meta-analysis","volume":"39","author":"Briceno","year":"2017","journal-title":"Neurol Res"}],"container-title":["Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1093\/neuros\/nyy385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:50:17Z","timestamp":1786121417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1093\/neuros\/nyy385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,29]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1093\/neuros\/nyy385","relation":{},"ISSN":["0148-396X","1524-4040"],"issn-type":[{"value":"0148-396X","type":"print"},{"value":"1524-4040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,29]]}}}